🏢 官网IRRARECodex · 实盘不做把握 9/10
北京时间·🕒 发布 04:05:38·⟳ 抓取 04:08:47 +3m09s·⚡ 决策 07-29 04:09:26 +39s·90.5 天前
Ultragenyx将于8月4日召开二季度业绩电话会
公司仅公告二季度业绩电话会时间和 webcast 链接，未披露业绩数据、指引变化、临床进展或商业化增量。
📄 原文RARE↗ 原文
Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
NOVATO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical co…
不做 Ultragenyx Pharmaceutical（RARE.US）
仅为财报电话会排期公告，未披露业绩、指引、临床或商业化新增信息，方向和edge均不足，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 low · price-in 风险 low ↗
关键理由
- 公司仅公告二季度业绩电话会时间和 webcast 链接，未披露业绩数据、指引变化、临床进展或商业化增量。
主要风险
- 8月4日正式财报和公司更新可能产生新催化，应由届时的新信号重新研判。
原文全文
展开原文 · 1,584 字
NOVATO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, August 4, 2026, to discuss its financial results and corporate update for the quarter ending June 30, 2026.
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at:
www.ultragenyx.com
.
Contact Ultragenyx
Investors
Joshua Higa
ir@ultragenyx.com
Media
Jess Rowlands
media@ultragenyx.com
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at:
www.ultragenyx.com
.
Contact Ultragenyx
Investors
Joshua Higa
ir@ultragenyx.com
Media
Jess Rowlands
media@ultragenyx.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。